One-year surgical outcomes of the PreserFlo MicroShunt in glaucoma: a multicentre analysis.

Alexander TannerFadi HaddadJulia Fajardo-SanchezEthan NguyenKai Xin ThongSarah Ah-MoyeNicole PerlMohammed Abu-BakraAvinash KulkarniSameer TrikhaGerassimos LascaratosMiles ParnellObeda KailaniAnthony J KingPavi AgrawalRichard SteadKonstantinos GiannouladisIan RodriguesSaurabh GoyalPirro G HysiSheng LimCynthia Yu-Wai-Man

Published in: The British journal of ophthalmology (2022)

The PreserFlo MicroShunt with MMC 0.4 mg/mL showed an overall success rate of 68.3% at 1 year, and led to significant IOP and medication reduction with a low rate of adverse effects.

Keyphrases

clinical trial
healthcare
study protocol
randomized controlled trial
adverse drug
optical coherence tomography